Science to practice: Will improved assessment of response to antiangiogenic therapies be achieved with contrast-enhanced gray-scale US?
McCarville et al have used gray-scale contrast-enhanced low-mechanical-index, and thus non-bubble-destructive, continuous US to quantitate tumor blood flow in mouse tumors engineered to simulate antiangiogenic therapy. They have shown that contrast-enhanced gray-scale US, unlike power or color Doppler US performed without contrast enhancement, is better able to depict and distinguish microvascular flow in subcutaneously implanted mouse tumors possessing different vascular phenotypes.
Kruskal
Jonathan B
JB
Department of Radiology, Beth Israel Deaconess Medical Center, 1 Deaconess Rd, Boston, MA 02215, USA. jkruskal@bidmc.harvard.edu
D020533:Angiogenesis Inhibitors / Q000378:metabolism* / Q000627:therapeutic use; D000818:Animals; D003287:Contrast Media / Q000493:pharmacokinetics*; D004195:Disease Models, Animal; D051379:Mice; D009369:Neoplasms / Q000098:blood supply / Q000000981:diagnostic imaging* / Q000188:drug therapy; D009389:Neovascularization, Pathologic / Q000000981:diagnostic imaging*; D014463:Ultrasonography / Q000379:methods
D020533:Angiogenesis Inhibitors; D003287:Contrast Media